MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Viking Therapeutics Inc

Gesloten

SectorGezondheidszorg

24.14 -6

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.01

Max

25.86

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

-35M

EPS

-0.32

Werknemers

36

EBITDA

-9.6M

-46M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+290.38% upside

Dividenden

By Dow Jones

Volgende Winsten

23 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-375M

2.9B

Vorige openingsprijs

30.14

Vorige sluitingsprijs

24.14

Nieuwssentiment

By Acuity

50%

50%

180 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Viking Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 feb 2025, 10:30 UTC

Top Nieuws

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23 dec 2024, 15:04 UTC

Top Nieuws

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dec 2024, 14:53 UTC

Top Nieuws

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4 nov 2024, 12:22 UTC

Top Nieuws

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4 nov 2024, 12:00 UTC

Top Nieuws

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4 nov 2024, 10:11 UTC

Populaire aandelen

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4 okt 2024, 12:01 UTC

Top Nieuws

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 okt 2024, 12:01 UTC

Top Nieuws

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20 sep 2024, 13:55 UTC

Top Nieuws

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25 jul 2024, 15:03 UTC

Winsten

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Peer Vergelijking

Prijswijziging

Viking Therapeutics Inc Prognose

Koersdoel

By TipRanks

290.38% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 100.25 USD  290.38%

Hoogste 164 USD

Laagste 38 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Viking Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

15

Buy

1

Hold

0

Sell

Technische score

By Trading Central

23.27 / 26.09Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

180 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.